MS

Manju Shukla

Active Director Director DIN 09575871
DIN 09575871 First appointment Apr 2022 Primary industry Chemicals
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Apr 2022
Shareholding value •••• Premium profile

About Manju Shukla

Data last updated:

Manju Shukla is a Director at Jsr Medicaments Private Limited (since 2022). The company operates in Chemicals. Jsr Medicaments Private Limited reported revenue of ₹1 Lakh (FY 2025).

DIN 09575871
Primary Designation Director
Industry Chemicals
First Appointment 18 Apr 2022
Oldest Company Age 4 yrs
Largest company Jsr Medicaments Private Limited · ₹1 Lakh (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Jsr Medicaments Private Limited U24230UR2022PTC013865
Director18 Apr 20222022₹1 Lakh (FY 2025)Active

Board colleagues of Manju Shukla

NameDINCompanyDesignation
Roshni Verma09575872Jsr Medicaments Private LimitedDirector

Directorship timeline

Open interactive timeline →
Jsr Medicaments Private Limited
Premium access

Shareholding and investment profile for Manju Shukla

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Manju Shukla

Manju Shukla currently holds 1 directorship: Jsr Medicaments Private Limited (Director, since 18 Apr 2022, revenue ₹1 Lakh (FY 2025)).

Manju Shukla was first appointed on 18 Apr 2022 as Director at Jsr Medicaments Private Limited.

The current boards of Manju Shukla's companies include Roshni Verma (Jsr Medicaments Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available